Day 1

June 17th, 2023

Day 2

June 18th, 2023

Day 3

June 19th, 2023

CET time zone

Day 1: 17 June 2023

Exploring Sarcopenia and Cachexia: Multidisciplinary Perspectives

Welcome to the first day of our Annual Conference on Sarcopenia, Cachexia, and Wasting Disorders. Discover world-renowned experts to discuss the latest research and advancements in the field.

Opening Session

12:30 - 13:45

HALL A

A - Opening Session

Chairs: Stefan Anker, Vickie Baracos and Gianluigi Savarese

Welcome
Stefan Anker

“Prometheus” basic science key note lecture:
Central mechanisms in cachexia: bench to bedside
Daniel Marks

“Hippocrates” clinical science key note lecture:
Small non-coding RNA profiling and cachexia in patients with cancer
Maurizio Muscaritoli

JCSM & SCWD – update 2023
Stephan von Haehling & Stefan Anker

Chairs & Speakers

General Sarcopenia

14:00-15:00

HALL A

B1 - Sarcopenia as a multisystem disorder

Chair: Ivan Aprahamian Sarcopenia and diabetes Gustavo Duque Sarcopenia and stroke/dysphagia Hidetaka Wakabayashi Sarcopenia and heart failure Gianluigi Savarese Discussion

Chairs & Speakers

15:00 - 16:15

HALL A

General Sarcopenia

B2 - The fat story of sarcopenia – the fat in muscle

Chair: Ivan Aprahamian & Marianne Hjermstad

Intermuscular fat infiltration in sarcopenia Gustavo Duque

Clinical implications of fat infiltration in sarcopenia Reshma Merchant Metabolic role of fat in muscle James Carson Targeting ACTIVIN receptors and the effect on muscle and fat tissue David Glass Discussion

Chairs & Speakers

HALL B

General Cachexia

C - Novel cancer cachexia biomarkers

Chairs: Nick Hoogenraad & Stephan von Haehling

The MIC-1/GDF15 story – biomarker and therapeutic target Samuel Breit

Targeted therapy relapse models to study cachexia development in lung cancer Swarnali Acharyya

Tumor genetic mutations and cancer cachexia – clinical findings Puneeth Iyengar

A geroscience approach to frailty biomarker discovery in cancer patients Emanuele Marzetti

Discussion

Chairs & Speakers

Coffee Break

16:15 - 17:15

POSTER AREA

Poster viewing 1

16:20 - 17:10

spacer

1.1 Cachexia – mechanisms, animal models I (posters 1-01 to 1-08)
Chairs: Denis Guttridge, Jochen Springer

1.2 Cancer cachexia I (posters 2-01 to 2-09)
Chairs: Joanne Reid, Florian Strasser

1.3 Physical activity & training; Nutrition & appetite (posters 5-01 to 5-05 and 6-01 to 6-06)
Chairs: Stuart Phillips, Adrian Slee

1.4 Diagnosis of cachexia / sarcopenia I (posters 3-01 to 3-12)
Chairs: Swarnali Acharyya, Philip Atherton

Chairs

HALL B

Rapid Fire Abstracts 1

16:20 - 17:00

Chairs: Elke Dworatzek, Maria Rohm, Erin Talbert

Tumor organoid-derived factors from cachectic pancreatic cancer patients induce a pro-inflammatory macrophage phenotype – role of macrophage migration inhibitory factor (1-15) Valerie d´Antonio (The Netherlands)

Elevated epicardial adipose tissue and aortic calcification, quantified from volumetric regional CT scans, are associated with postoperative complications in complex rectal cancer (3-23) Dinh Mai (UK)

Validation of a deep learning model for automatic segmentation of skeletal muscle and adipose tissue on L3 abdominal CT images (3-30) David van Dijk (The Netherlands)

The Rho GTPase inhibitor, RhoGDIα is a negative regulator of muscle mass and upregulated in sarcopenic human muscle (4-04) Lisbeth Møller (Denmark)

Extracellular vesicles are possible mediators of the liver-muscle axis in sarcopenia associated to liver disease (4-13) Manuela Merli (Italy)

Enhanced glutamine availability exerts different effects on protein and amino acid metabolism in muscles of healthy and septic rats (7-02) Milan Holecek (Czech Republik)

A novel first-in-class USP19 inhibitor for the treatment of cancer-induced muscle atrophy (7-05) Richard Wilkinson (UK)

Developing an evidence and theory based multimodal integrative intervention for the management of renal cachexia: a theory of change (7-08) Carolyn Blair (UK)

Chairs

17:15 - 18:30

HALL A

General Sarcopenia

D - Sarcopenia in lung disease: interplay with chronic conditions

Chairs: Abigail Mackey & Hidetaka Wakabayashi

Definition, diagnostic criteria and treatment of respiratory sarcopenia Akira Tamaki

Cytokine signaling in adipose tissue browning and muscle wasting in CKD Robert Mak COPD and other chronic diseases Marielle Engelen Sarcopenia in cardio-respiratory illnesses Stephan von Haehling Discussion

Chairs & Speakers

HALL B

General Cachexia

E - Liver metabolism in cancer and cachexia

Chairs: Maria Rohm & Jochen Springer

Cancer-induced rewiring of metabolism and zonation in the liver Shinpei Kawaoka

Targeting bile acid metabolism to counteract cancer cachexia Laure Bindels Liver mitochondrial function in cancer cachexia Marilia Seelaender Liver NAD+ metabolism in cancer- and chemotherapy-induced cachexia Fabio Penna Discussion

Chairs & Speakers

Register Now!

Embrace this opportunity to redefine the field and create lasting impact in the lives of patients worldwide.

Day 2: 18 June 2023

Comprehensive Exploration of Cancer Cachexia and Aging-Related Sarcopenia

Doscover the second day of our programme, dedicated to exploring the complexities of cancer cachexia and aging-related sarcopenia. With a stellar lineup of international experts presenting their latest research and engaging in insightful panel discussions

café

08:00-08:50

FOYER

Ken Fearon Career Café

09:00-10:15

HALL A

NUTRITION

F - Nutritional issues in cachexia

Chairs: Florian Strasser & Joanne Reid

Appetite, food quantity and quality in cancer cachexia
Alessio Molfino

Gut barrier, nutrient absorption and cachexia
Laure Bindels

Exercise, nutrition and omega-3 PUFA Interventions for kidney cachexia
Adrian Slee

Examining biological sex variability in cancer-induced cachexia
Nicholas P. Greene

Discussion

Chairs & Speakers

HALL B

Mechanisms, Diagnostics (Basic / Translational)

G - New mechanisms of cancer cachexia

Chairs: Andrea Bonetto & Paola Costelli

Tissue crosstalk during cancer cachexia: consequences of altered metabolic networks
Selma Masri

Inflammation as target in cancer cachexia
Erin E Talbert

Examining the relationship between mitochondrial function and muscle force in cancer cachexia
Luca Delfinis

Deletion of FNDC5/Irisin protects against cancer induced cachexia syndrome
Fabrizio Pin

Discussion

Chairs & Speakers

Coffee Break

10:15-11:15

POSTER AREA

Poster viewing 2

10:20-11:10

spacer

2.1 Cachexia – mechanisms, animal models II (posters 1-09 to 1-16) Chairs: Denis Guttridge, Jochen Springer

2.2 Cancer cachexia II (posters 2-17 + 2-19 to 2-26) Chairs: Joanne Reid, Florian Strasser

2.3 Muscle wasting & sarcopenia I (posters 4-01 to 4-11) Chairs: Marielle Engelen, Olav Rooyackers

Chairs

HALL B

Rapid Fire Abstracts 2

10:20-10:50

Chairs: Laurence Genton, Marianne Hjermstad

The association between protein intake and skeletal muscle parameters in patients with localized renal cell cancer (5-01) Alina Vrieling (The Netherlands)

Preoperative supportive nutrition at major cancer surgery in weight-losing patients (5-03) Britt-Marie Iresjö (Sweden)

Cancer-associated anorexia: DNA methylation signatures in patients with lung cancer (5-04) Giovanni Imbimbo (Italy)

Higher fibroblast growth factor 23 levels are associated with low exercise capacity in patients with chronic heart failure: Results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF) (6-04) Ryosuke Sato (Germany)

Anti-RANKL treatment attenuates mitochondria deterioration and suppresses macrophage infiltration during sarcopenia (7-01) Can Cui (China)

Muscle protein synthesis with a hybrid dairy and plant-based protein blend (P4) is equal towWhey protein in a murine aging model after fasting (7-04) Francina Dijk (The Netherlands)

Chairs

11:15-12:30

HALL A

GENERAL SARCOPENIA

H - Update on aging and immobilisation related sarcopenia

Chair: Philip Atherton, UK & Robert Mankowski

Effects of aging on human muscle atrophy with immobilization
Stuart Phillips

The human neuromuscular junction in ageing and exercise
Abigail Mackey

The role of nutrition in aging: appetite loss
Ivan Aprahamian

Brain muscle cross talk
Reshma Merchant

Discussion

Chairs & Speakers

HALL B

GENERAL CACHEXIA

I - The role of extracellular vesicles in wasting

Chairs: Samuel Breit & Adrian Slee

Tumour-derived exosomes
Joanna Lima

Intracellular peptides: potential biomarkers and therapeutic targets
Patrícia Reckziegel

Extracellular vesicles and inflammation: from cachexia to COVID-19
Marilia Seelaender

Tumor-host cross-talk: focus on the extracellular vesicles
Paola Costelli

Discussion

Chairs & Speakers

Lunch Break

12:30-13:30

Lunch Break

13:30-14:45

HALL A

Cancer Cachexia Therapeutics

J - Endpoints in cancer cachexia clinical trials

Panel: Jeffrey Crawford, Jose Garcia, Frank Misselwitz, Maurizio Muscaritoli, Richard Skipworth

Physical function endpoints
Barry Laird

Appetite and dietary intake endpoints in cancer cachexia trials
Tora Solheim

Quality of life endpoints
Marianne Hjermstad

Approvable endpoints for cancer cachexia – an evolving field
Stefan Anker

Discussion

Panel & Speakers

HALL B

Cancer Cachexia Therapeutics

K - New cachexia treatment approaches on the horizon

Chairs: Mauricio Berriel Diaz & Nicolaas Deutz

Anti-Fn14 therapy for cancer cachexia
Nick Hoogenraad

Peptide-based therapeutic approaches in cancer cachexia
Stephan Herzig

Targeting the TGFbeta pathway
Marcus D. Goncalves

Modulating metabolic pathways – impact on cachexia and malnutrition
Bei B. Zhang

Discussion

Chairs & Speakers

Coffee Break

14:45-15:45

POSTER AREA

Poster viewing 3

spacer

3.1 Muscle wasting & sarcopenia II (posters 4-12 to 4-22)
Chairs: Nick Hoogenraad, Robert Mak

3.2 Therapeutic development pre-clinical/clinical (posters 7-01 to 7-12)
Chairs: Paola Costelli, Sander Rensen

3.3 Diagnosis of cachexia / sarcopenia II (posters 3-13 to 3-22)
Chairs: Swarnali Acharyya, Philip Atherton

Chairs

HALL B

Rapid Fire AbstractS 3

Chairs: Elke Dworatzek, Lykke Sylow, Sarah Judge

Growth of GL261 glioblastoma tumors induced delayed body weight gain and stunted skeletal muscle growth in pediatric mice (1-01) Nicholas Jamnick (USA)

Sexual dimorphism in the development of cancer cachexia in ApcMin/+ mice (1-02) Benedicte Guegan (France)

Hepatic metabolism alterations and effects of niacin supplementation in experimental cancer- and chemotherapy-induced cachexia (1-05) Natalia E Cortez (Italy)

Role of fibroadipogenic progenitors in pancreatic cancer cachexia (1-11) Ashok Narasimhan (Canada)

Regulation of pancreatic cancer-induced muscle wasting through the obestatin/GPR39 system (1-14) Icia Santos-Zas (Spain)

Microbiota-derived secondary bile acids to tackle cancer cachexia (2-04) Morgane Thibaut (Belgium)

First-in-patient (Phase 1b) study of the GDF-15 inhibitor ponsegromab in patients with cancer and cachexia: safety, tolerability, and exploratory measures of efficacy (2-07) Jeffrey Crawford (USA)

Scalable and privacy-preserving AI can characterise and discover more cachectic cancer patients compared to ICD codes and NLP based approaches (2-09) Judith Sayers (UK)

Chairs

15:45-17:00

HALL A

Cancer Cachexia Therapeutics

L - Emerging trials in cancer cachexia

Chairs & Panelists: Stefan Anker, Vickie Baracos, Frank Misselwitz, Maurizio Muscaritoli, Stephan von Haehling

Update on ponsegromab early clinical trial
Jeffrey Crawford

Multimodal intervention for cancer cachexia – MENAC study
Barry Laird

Pilot study of macimorelin for cancer cachexia
Jose Garcia

Discussion

Chairs & Panelists

HALL B

Mechanisms, Diagnostics (Basic / Translational)

M - Tissue crosstalk in cancer cachexia

Chair: Stephan Herzig & Fabrizio Pin

Adipocytokines in patients with cancer cachexia
Richard Skipworth

Crosstalk of lipid metabolism and inflammation drives cachexia
Maria Rohm

Liver-derived factors contributing to cancer cachexia
Mauricio Berriel Diaz

Mechanisms of bioamplification in cancer cachexia
Daniel Marks

Discussion

Chairs & Speakers

Break

17:00-17:15

Break

17:15-18:30

HALL A

Cancer Cachexia Therapeutics

N - Therapy of sarcopenia and cachexia: emerging trials and late breaking results

Chairs & Panelists: Stefan Anker, Jose Garcia, Barry Laird, Maurizio Muscaritoli, Richard Skipworth

Treating the malignancy associated weight loss and anorexia with the ghrelin receptor agonist Anamorelin when administered in adult patients with non-small cell lung cancer (NSCLC) and cachexia
Daniela Domnica Rotaru

Non-clinical and clinical development of S-pindolol benzoate in cancer cachexia in patients with advanced non-small cell lung and colo-rectal cancer
Frank Misselwitz

Update on ponsegromab early clinical trial
Jeffrey Crawford

BIOPHYTIS BIO101: a candidate treatment for muscle diseases
Cendrine Tourette

Discussion

Chairs & Panelists

HALL B

Mechanisms, Diagnostics (Basic / Translational)

O - New insights into the mechanisms of cancer-associated muscle wasting

Chair: James Carson & Julien Gondin

Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of activin
Teresa Zimmers

FoxP1 is a transcriptional repressor associated with cancer cachexia that induces skeletal muscle wasting and weakness
Andrew Judge

Liver metastases enhance the pro-cachectic signaling in colorectal cancer hosts
Andrea Bonetto

Cancer preferentially causes fast muscle mass loss through UBR2-mediated ubiquitylation of myosin heavy chain IIb and IIx
Yi-Ping Li

Discussion

Chairs & Speakers

Register Now!

Embrace this opportunity to redefine the field and create lasting impact in the lives of patients worldwide.

Day 3: 19 June 2023

Exploring the Intricacies of Muscle Wasting and Microbiome in Cancer Cachexia

Day three of our programme plunges us into the intricacies of muscle wasting and the microbiome’s influence in cancer cachexia. We are pleased to present a distinguished gathering of international experts, eager to share their groundbreaking research and partake in dynamic discussions.

Award Session

8:00-8:50

HALL A

P - Young Investigators Award Session

Chairs: James Carson, Paola Costelli, Daniel Marks, Maurizio Muscaritoli, Maria Rohm, Jochen Springer, Teresa Zimmers

Mechanisms of skeletal muscle atrophy in patients with early breast cancer treated with chemotherapy: insights from acute and chronic measurements (1-12) Joris Mallard (France)

Neutrophil-derived S100a8/a9 as a mediator of adverse cardiac remodeling in cancer-associated cachexia (2-01) Parham Diba (USA)

Cachexia, sarcopenia and bone markers in patients with heart failure and hyperkalemia: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF) (4-15) Guglielmo Fibbi (Germany)

Exercise decreases catabolic protein signaling in rat skeletal muscle 40 days post-burn (6-01) Dorien Dombrecht (Belgium)

Loss of hypoxia signalling-mediated PGC-1a expression underlies age-related loss of muscular adaptation to exercise (6-06) Yori Endo (USA)

Assessing the effect of intra-abdominal malignancy on the impact of a short-term homebased unsupervised exercise on skeletal muscle mitochondrial OXPHOS function (7-12) Thomas Smart (UK)

Chairs/Judges

Mechanisms, Diagnostics (Basic / Translational)

9:00-10:15

HALL A

Q - CURRENT LIMITATIONS IN PRESERVING MUSCLE IN CANCER

Chairs: Andrea Bonetto, USA, Erin Talbert, USA

Pathological remodeling of respiratory muscles during cancer: mechanisms and therapeutic targets
Sarah Judge, USA

Molecular basis and clinical relevance of insulin resistance in cancer cachexia
Lykke Sylow, Denmark

Neuromuscular electrical stimulation limits muscle weakness and wasting and modulates satellite cell function and niche during cancer cachexia
Julien Gondin, France

Chemotherapy-specific effects on cardiorespiratory status and body composition
Ashley Smuder, USA

Discussion